GENE ONLINE|News &
Opinion
Blog

2021-09-29| In-DepthSpecial

Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?

by Rajaneesh K. Gopinath
Share To
A controversy session at the 2021 ESMO Annual Meeting focused on the debate where experts weighed on which among the two emerging cancer therapies—CAR T-cell therapy or bispecific antibodies would prevail in the long fight against cancer.

CAR-T therapy involves enhancing the cytotoxic ability of a patient's naïve T-cells by genetic manipulation. A foreign DNA is first introduced to produce the chimeric antigen receptor (CAR) on the T-cell surface, and the resulting CAR T-cells are expanded in vitro. They are then re-introduced to the patient, where they identify a specific cell surface antigen on cancer cells and attack them.

On the other hand, bispecific antibodies work by binding to two targets; one present on the cancer cell and another present on T cells. This way, a tumor cell and an activated immune cell are brought together to eradicate cancer.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top